semaglutide and cardiovascular Outcomes in Patients with Type 2 Diabetes FDA Clears Semaglutide For Cardiac

Acid Reflux as a Reported Side Effect in Clinical Trials Data from Zepbound and tirzepatide clinical trials recorded acid reflux or heartburn in approximately 9-15% of participants at therapeutic doses, with higher rates reported in some real-world observational studies

Scheduling an appointment or gathering more information is simple

AI-Powered Food Recognition Just take a photo

a Simultaneous participation in any other clinical trial receiving an investigational medicinal product b Patients who attended the final scheduled visit c Patients who completed treatment with assigned treatment according to the end-of-trial form d 412 patients were randomized and 411 were included in the FAS

The most commonly reported adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation